CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTX-8371’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CTX-8371 overview

CTX-8371 is under development for the treatment of bladder cancer, triple negative breast cancer, metastatic melanoma, head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, non-small cell lung cancer, Hodgkin Lymphoma and colorectal cancer. It is a bi-specific monoclonal antibody which acts by targeting PD-1 and its ligand PD-L1. The drug candidate is developed based on StitchMabs platform technology. It is administered through intravenous route.

Compass Therapeutics overview

Compass Therapeutics a biotechnology company. The company’s product pipeline includes CTX-471, CTX-009, CTX-8371 and others. It develops transformational therapies for cancer, inflammation and autoimmune diseases. The company is into the discovery of antibody-drug candidates with a focus on T cells, NK cells and macrophages. Compass Therapeutics develops both agonists and antagonists, which facilitate the development of monotherapies and combination therapies. It utilizes Sympleitope technology platform for epitope screening and selection; and StitchMabs, a novel multi specific antibody screening platform that combines monoclonal antibodies into various specific formats. Compass Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of CTX-8371’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.